Trial Profile
A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of (14C)-CC-220 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2017
Price :
$35
*
At a glance
- Drugs Iberdomide (Primary)
- Indications Multiple myeloma; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 24 Oct 2017 Status changed from recruiting to completed.
- 29 Sep 2017 New trial record